Holen Sie sich die Stockscreener-App
4.44
5.13%
-0.24
Handel nachbörslich:
4.50
0.06
+1.35%
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
RXRX Stock: Analyzing the Dive and Its Impact - StocksToTrade
Update Report: Is Recursion Pharmaceuticals Inc stock overvalued by current metricsCEO Change & Precise Buy Zone Tips - moha.gov.vn
Recursion Pharmaceuticals: Upgrading To BuyMy Most Surprising Call Of 2025 (RXRX) - Seeking Alpha
RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes
Is Recursion Pharmaceuticals Stock Attractive? - Trefis
Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet - Finviz
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next - ts2.tech
Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet - Insider Monkey
What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - simplywall.st
U.S. stock market movement | AI healthcare concept stock Recursion continues to rise 3.8% in pre-market trading, Morgan Stanley raises rating + Cathie Wood increases position. - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX) - The Globe and Mail
JPMorgan has upgraded Recursion (RXRX.US) to an 'Overweight' rating, with its core pipeline candidate REC-4881 expected to become a blockbuster drug. - 富途牛牛
Backed by Nvidia, Recursion Soars 11% Following Bullish Analyst Call and Clinical Trial Update - NAI500
Why Recursion Pharmaceuticals stock vaulted 11% higher on Wednesday - MSN
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday - Nasdaq
Stock Traders Buy Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals: Is Now the Time to Invest? - StocksToTrade
Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade - marketscreener.com
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why - Benzinga
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today - Stocktwits
10 Best NASDAQ Stocks Under $10 to Buy - Insider Monkey
Recursion Pharmaceuticals Triumphs in FAP Trial, Boosting Investor Confidence - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral' - marketscreener.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded to Overweight at JPMorgan Chase & Co. - MarketBeat
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan - TipRanks
Recursion Pharmaceuticals stock upgraded by JPMorgan on MEK inhibitor potential - Investing.com India
Recursion Pharmaceuticals (NASDAQ:RXRX) Nasdaq Index Fund Spotlight - Kalkine Media
Nikko Asset Management Americas Inc. Sells 239,589 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Insider Sale: Market Implications - timothysykes.com
Recursion rises on new data for asset for polyps - MSN
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha
Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)? - simplywall.st
Jump Financial LLC Purchases 558,848 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating - TipRanks
Norges Bank Buys Shares of 3,169,938 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is There an Opportunity in Recursion Pharmaceuticals After Recent AI Drug Discovery Rally? - Yahoo Finance
Recursion Pharmaceuticals Reports Positive TUPELO Trial Results - TipRanks
Recursion Pharmaceuticals reports positive TUPELO trial results - MSN
Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - simplywall.st
Why Recursion Pharamaceuticals Topped the Market Today - MSN
Why Recursion Pharamaceuticals Topped the Market Today - The Motley Fool
Recursion Pharmaceuticals: Unraveling the Surge - timothysykes.com
Recursion Pharmaceuticals (RXRX) up 6.5% since last earnings report: Can it continue? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative
Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals - TipRanks
Why Are Shares Of Recursion Pharmaceuticals Higher Today? - Benzinga
Recursion Pharmaceuticals Jumps as FAP Drug Candidate Shows Durable Efficacy - TradingPedia
Why Recursion Pharmaceuticals Shares Are in Focus Today - TipRanks
Recursion's Tupelo trial phase 1b/2 results show polyp burden reductions in FAP at 25 weeks - marketscreener.com
Recursion Pharmaceuticals stock surges after positive FAP trial data By Investing.com - Investing.com UK
Recursion’s FAP drug shows durable polyp reduction in phase 1b/2 trial - Investing.com
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):